Relay Therapeutics, Inc. (RLAY)
NASDAQ: RLAY · Real-Time Price · USD
17.28
-1.07 (-5.83%)
At close: Nov 2, 2026, 4:00 PM EST
17.30
+0.02 (0.12%)
After-hours: Nov 2, 2026, 7:30 PM EST
Relay Therapeutics Stock Forecast
Stock Price Forecast
According to 13 analysts polled by S&P Global, Relay Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $27.58. The average 1-year stock price forecast is 59.61% higher than the current stock price, while the lowest is $20 (+15.74%) and the highest is $32 (+85.19%).
Price Target: $27.58 (+59.61%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Relay Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 10 | 11 | 11 | 10 | 10 |
| Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 12 | 14 | 14 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Buy Initiates $26 | Buy | Initiates | $26 | +50.46% | Oct 27, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $29 | Buy | Maintains | $29 | +67.82% | Oct 26, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains $25 | Buy | Maintains | $25 | +44.68% | Oct 23, 2026 |
| JonesTrading | JonesTrading | Buy Maintains $20 | Buy | Maintains | $20 | +15.74% | Sep 28, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $28 → $29 | Buy | Reiterates | $28 → $29 | +67.82% | Aug 20, 2026 |
Financial Forecast
Revenue This Year
11.19M
from 15.36M
Decreased by -27.16%
Revenue Next Year
17.91M
from 11.19M
Increased by 60.15%
EPS This Year
-1.61
from -1.61
EPS Next Year
-1.63
from -1.61
EPS and Forward PE are based on non-GAAP adjusted numbers.